Italfarmaco Options Inhaled Teicoplanin For MRSA Lung Infections
Italfarmaco and Neupharma plan to collaborate on the development of a new inhaled formulation of a Gram-positive targeted antibiotic for MRSA infections in cystic fibrosis.
You may also be interested in...
Orphan lung disease firm tries to sell Phase III setback in aPAP as a “successful failed study” but investors disagree, cutting Savara’s share price by three-quarters. Biotech hopes to talk with regulators after deeper dive into dataset.
Updates from the holiday season include a Phase III failure for Pfizer's MRSA vaccine, AbbVie's submission of upadacitinib for rheumatoid arthritis and several year-end US approvals and FDA actions.
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.